{"id":728562,"date":"2023-02-03T07:33:45","date_gmt":"2023-02-03T12:33:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/"},"modified":"2023-02-03T07:33:45","modified_gmt":"2023-02-03T12:33:45","slug":"monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/","title":{"rendered":"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Feb.  03, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U24vXMxLf-YFNJ4urba_W6p0EPfIEEhr9nL9f3t3VLLpl90U6BW-L4gfUZdPadbX7up0jouQGWjv9IsqXZnJNpRQQzXZ8MyWUiJKOZS2EmE=\" rel=\"nofollow noopener\" target=\"_blank\">Monte Rosa Therapeutics, Inc.<\/a> (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:<\/p>\n<ul type=\"disc\">\n<li>Guggenheim Oncology Conference in New York, on February 9, at 2:45 p.m. ET\n<\/li>\n<li>BMO Virtual Biopharma Spotlight Series on February 10, 2023, at 10:00 a.m. ET\n<\/li>\n<li>SVB Securities Virtual Global Biopharma Conference on February 14, 2023, at 11:20 a.m. ET\n<\/li>\n<li>Wells Fargo Virtual Targeted Protein Degradation Summit on February 21, 2023, at 3:00 p.m. ET\n<\/li>\n<li>Cowen\u2019s 43rd Annual Health Care Conference in Boston, on March 7, 2023, at 10:30 a.m. ET<\/li>\n<\/ul>\n<p>Webcasted presentations will be accessible via the \u201cEvents &amp; Presentations\u201d section of the company\u2019s investor site at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K5PeW92Qcqgja7AFfeX60OqPEFkUmYtEUJ_EGmPI49cOsbfYYXp6Y3GeYKA58OoZBbD5h34m2gKEc6ChJy6UnshzC4OjE2804P8wlLheGU8=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.monterosatx.com\/<\/a>, and an archived version will be made available for 30 days following the presentation.<\/p>\n<p>\n        <strong>About Monte Rosa<\/strong><br \/>\n        <br \/>Monte Rosa Therapeutics is a biotechnology company developing novel molecular glue degrader (MGD) medicines for patients living with serious diseases such as oncology, autoimmune and inflammatory diseases. MGDs are small molecule protein degraders designed to employ the body\u2019s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company\u2019s QuEEN\u2122 (Quantitative and Engineered Elimination of Neosubstrates) platform enables it to rapidly identify protein targets and design highly selective degraders by combining diverse libraries of proprietary MGDs with in-house proteomics, structural biology, AI\/machine learning, and computational chemistry capabilities. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pbaabyJIcVSOpdnlD5Y0Tiy_XFOiKkPq5JkXZHVMRM1uwjtHg_moK-QdAsXnmDxW-Z9C5Ce0zHTjKnmhuykDhswd_mdLZLTVwQTbs6ePAz4=\" rel=\"nofollow noopener\" target=\"_blank\">www.monterosatx.com<\/a><\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Shai Biran, Monte Rosa Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8mYH-Vkx9rVGV2T6O2oUrK2PFW4sQoxSbBfZ0aTzLcRoLu8YVcP2Ybo33VFrdbc96PZQ-bEnOBB0cjMZRNoxnutDxCgnM8OsBChdebjf6AE=\" rel=\"nofollow noopener\" target=\"_blank\">ir@monterosatx.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Dan Budwick, 1AB<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kQI7JAmeUa3bpB86LdFGVmPXgBymMhDUxC8zOigp8QmeetFkn1Qgaphq5NwH8du9W7fau2l0O5VYi1o6P3riuw==\" rel=\"nofollow noopener\" target=\"_blank\">dan@1abmedia.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTdmOThmYzEtYjExZi00NGZhLThlMzktODcxZjE5YzM1MmQ0LTEyMjEwOTg=\/tiny\/Monte-Rosa-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events: Guggenheim Oncology Conference in New York, on February 9, at 2:45 p.m. ET BMO Virtual Biopharma Spotlight Series on February 10, 2023, at 10:00 a.m. ET SVB Securities Virtual Global Biopharma Conference on February 14, 2023, at 11:20 a.m. ET Wells Fargo Virtual Targeted Protein Degradation Summit on February 21, 2023, at 3:00 p.m. ET Cowen\u2019s 43rd Annual Health Care Conference in Boston, on March 7, 2023, at 10:30 a.m. ET Webcasted presentations &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monte Rosa Therapeutics to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728562","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monte Rosa Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events: Guggenheim Oncology Conference in New York, on February 9, at 2:45 p.m. ET BMO Virtual Biopharma Spotlight Series on February 10, 2023, at 10:00 a.m. ET SVB Securities Virtual Global Biopharma Conference on February 14, 2023, at 11:20 a.m. ET Wells Fargo Virtual Targeted Protein Degradation Summit on February 21, 2023, at 3:00 p.m. ET Cowen\u2019s 43rd Annual Health Care Conference in Boston, on March 7, 2023, at 10:30 a.m. ET Webcasted presentations &hellip; Continue reading &quot;Monte Rosa Therapeutics to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T12:33:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences\",\"datePublished\":\"2023-02-03T12:33:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"name\":\"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=\",\"datePublished\":\"2023-02-03T12:33:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) &#8212; Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events: Guggenheim Oncology Conference in New York, on February 9, at 2:45 p.m. ET BMO Virtual Biopharma Spotlight Series on February 10, 2023, at 10:00 a.m. ET SVB Securities Virtual Global Biopharma Conference on February 14, 2023, at 11:20 a.m. ET Wells Fargo Virtual Targeted Protein Degradation Summit on February 21, 2023, at 3:00 p.m. ET Cowen\u2019s 43rd Annual Health Care Conference in Boston, on March 7, 2023, at 10:30 a.m. ET Webcasted presentations &hellip; Continue reading \"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-03T12:33:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences","datePublished":"2023-02-03T12:33:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/","name":"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=","datePublished":"2023-02-03T12:33:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MjE0OSM1Mzg0NDE2IzIyMDk1NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monte Rosa Therapeutics to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728562"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728562\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}